The Study Of Marker On Verification Of The HIV/AIDS Spleen Deficiency Syndrome Proteomics

ObjectiveSignificant differences between the proteins of the present study of the pre-screened iTRAQ spleen deficiency syndrome AIDS patients were validated by Western Blot techniques.This experiment is to obtain spleen deficiency syndromes characteristic protein expression profile. Through the appropriate medicine for the treatment of patients observed characteristic changes in protein expression, exploring the efficacy of drugs and syndromes characterized by the expression of proteins between changes.MethodsWe collect the healthy control group, spleen deficiency syndrome AIDS patients before treatment and after 12 months of peripheral blood serum was separated and extracted protein after protein digestion Western Blot test. Using the gray value image J analysis software, each lane derived target protein albumin gray value corresponding gray value for comparison, obtained relative gray value, then the relative gray of each antibody in normal group values and relative gray value of patient group into Graph Pad Prism 5 software. Using IBM SPSS Statistics V20.0 software for statistical analysis method. Count data using Fisher exact test. Normally distributed data using mean±standard deviation (x±s) represented. By P<0.05 as the difference between the standard criteria.Results1.Comparison of AIDS medication before spleen deficiency syndrome and normal control group, RBP4 in spleen deficiency syndrome of AIDS up-regulated, and the difference was statistically significant (P<0.05), consistent with iTRAQ screening results; C7 of AIDS up-regulation of spleen deficiency syndrome, the difference was statistically significant (P<0.05), consistent with iTRAQ filter results.2.Spleen deficiency syndrome of symptoms before treatment comparison with normal control group, RBP4 expression in the asymptomatic group of spleen deficiency increases, the difference was statistically significant (P<0.05), consistent with iTRAQ screening results,with low protein content compared to AIDS. C7 is down-regulated in asymptomatic spleen deficiency syndrome group, but iTRAQ screening results are inconsistent.3.CD4+ and CD8 were stable increasing,CD4+is statistically significant (P<0.05).CD8 is not statistically significant. In AIDS patients of Spleen deficiency syndrome treated.by drugs after 48 weeks. CD4+and CD8 were stable increasing,CD4+is statistically significant (P<0.05),compared with 48 weeks asymptomatic after treatment of spleen deficiency syndrome patients.4.The front and rear of spleen deficiency syndrome AIDS medication comparison, RBP4 is down-regulated in the spleen deficiency syndrome of AIDS medication, the difference was statistically significant (P<0.05). C7 is up-regulated in the spleen deficiency syndrome of AIDS medication.5.The first symptom of spleen deficiency syndrome drug, comparison, RBP4 expression in asymptomatic spleen deficiency group, the difference was statistically significant (P<0.05), but compared to the low protein content of AIDS.C7 down-regulated in the asymptomatic group of spleen deficiency syndrome.Conclusions1.AIDS of spleen deficiency syndrome characterized has the presence of protein. RBP4 is progress characteristic protein spleen of deficiency syndrome asymptomatic to AIDS,probablly related to oxidative stress,inflammation or metabolic syndrome-related reactions.C7 is AIDS of spleen deficiency syndrome characterized expression of proteins,probablly related to the immune response functions and cell lysis and cell death process involves relevant.2.The present study result that expression levels of RBP4 with spleen deficiency syndrome of traditional Chinese medicine diagnosis and treatment of AIDS treatment effect was consistent trend.This has efficacy evaluation significance for spleen deficiency syndrome AIDS treatment.